At the ISPOR Warsaw 2019 regional conference, a panel examined country experiences with managed entry agreements and their impact on improving access to innovative oncology therapies.
This article summarizes the lessons learned from implementing managed entry and multi-year, multi-indication agreements in different regional contexts.
Ken Beers joins CRA's Life Sciences Practice as Vice President
CRA is proud to welcome Kenneth J. Beers as a vice president in the Life Sciences Practice. Mr. Beers supports biopharmaceutical clients across a range of...